Clinical Trials 101 | Alzheimer's Prevention Registry

You are here

Clinical Trials 101

Drugmaker reverses course, plans to seek FDA approval for Alzheimer's treatment

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for aducanumab, an experimental treatment for early Alzheimer's disease, Biogen and its Japanese partner Eisai announced on Tuesday.

We Will Find a Breakthrough for Alzheimer's Disease

I have spent my entire career interested in the mysteries of the brain: what it looks like, how it works and what happens when it doesn’t. Alzheimer’s disease has been the primary focus of my professional life, starting as a young researcher looking at brain scans, and leading up to now, as the head of the research program at the Alzheimer’s Association.

MRI may help doctors differentiate causes of memory loss

A UCLA-led study has found that MRI scans can help doctors distinguish whether a person's memory loss is being caused by Alzheimer's disease or by traumatic brain injury.

Biogen Dropped Me From Their Cancelled Alzheimer’s Study; Now They’re Bringing It Back

I wasn’t yet fully awake this morning when I started poking through my Facebook feed and saw the head-spinning news that Biogen had reversed itself and was now asking the FDA to approve its experimental Alzheimer’s drug.

PROMOTING HEALTHY BEHAVIOR

Amy Bleakley's research runs the gamut from adolescents to Alzheimer's disease, dental cavities to clinical trials, but she says the topics are not as different as they might appear.

Alzheimer’s research reset

After some costly and disappointing drug trial failures, the field welcomes a funding surge, tools for tracking disease, and interdisciplinary collaborations to tackle one of science’s most stubborn puzzles.

A road map for including Latinos and African Americans in Alzheimer’s research

Alzheimer’s disease is the only leading cause of death in the U.S. that is still on the rise and that does not have a current effective treatment or cure. The limited inclusion of Latinos and African Americans in research will only worsen the outlook, though the success of efforts bubbling up across the country could help us keep up with the disease.

China approves Alzheimer's drug, inviting fresh debate in field with few successes

In a decision likely to stir scientific debate across the world, China's health regulator conditionally approved a new Alzheimer's drug for patients with mild-to-moderate forms of the neurodegenerative disease. 

Why Didn’t She Get Alzheimer’s? The Answer Could Hold a Key to Fighting the Disease

Researchers have found a woman with a rare genetic mutation that has protected her from dementia even though her brain has developed major neurological features of the disease.